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ABSTRACT

A novel class of methyl esters of substituted 4-oxo-2butenoic acids and their derivatives are disclosed along with
the surprising use property of these compounds as a bacteriostatic agents for humans or non-humans against mycobacteria. These compounds include: 4-( 4-Ethoxy-phenyl)-2(N'-fiuoren-9-ylidene-hydrazino )-4-oxo-but-2-enoic acid
methyl ester; 4-( 4-Ethoxy-phenyl)-2-(N'-fiuoren-9-ylidenehydrazino )-2-hydroxy-4-oxo-butyric acid methyl ester;
2-( 4-Bromo-phenylamino )-5,5-dimethyl-4-oxo-hex-2-enoic
acid methyl ester; A pharmaceutical composition is disclosed as well as the method of treating human and nonhumans infected with M. tuberculosis and related mycobacteria.
5 Claims, 1 Drawing Sheet
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METHYL ESTERS OF SUBSTITUTED 40X0-2-BUTENOIC ACID FOR TREATMENT
OF TUBERCULOSIS

sive: a 3 drugs regimen is needed (more than $500/month
cost per patient). Thus the major problems faced in tuberculosis control are poor infrastructures for diagnosis and
drug supply. The failure of patients to complete therapy as
well as inappropriate mono-therapy has led to the emergence
and distribution of strains of Mycobacterium tuberculosis
resistant to every available chemotherapy (Bloom B R and
Murray C J L, Science (1992) 257, 1055-1064). Such
organisms will not remain confined to the Third World or to
the poor and indigent of developed countries. The recent
documentation of the spread of a single clone of multi-drug
resistant Mycobacterium tuberculosis (the "W" strain)
throughout the continental United States and Europe highlights the danger of an airborne pathogen in our global
society (Bifani P J, et al., JAMA (1996) 275, 452-457).
The patent literature has numerous disclosures of Heterocyclic oxo-butenoic (crotonic) compounds: They include
Pamukci (6,232,312) describes crotonic acid derivatives
(column 22, lines 43-58) for the treatment of colonic
polyps;
Jones et al (6,121,450) discloses crotonic acid derivatives
(column 8, line 34; column 78, line 24 and at example
340) as steroid modifiers in treating breast cancer (column
1, lines 55-58);
Kalden, et al (5,334,612) discloses compounds said to be
useful for treating AIDS including derivatives of carboxylic acid (column 9, line 31) and pyrrolidine (column 7,
line 24);
Nicolai, et al (6,180,651) discloses many anti-inflammatory
and analgesic compounds, including adenocarcinoma
(column 1, line 55), which includes heterocyclic alcoholesters (column 11, lines 1-16) and butanoic acid derivatives (many Examples including 47 through 162);
Brown (6,066,670) describes an anti-viral admixture containing crotonic acid for treating tumors (see Abstract);
Girard, et al (5,308,852) discloses many compounds including butanoic acid derivatives (see Methods B and C of
schemes II and III) which compounds which are said to
inhibit tumor metastasis (column 7, line 56 and column 8,
line 4);
Harwell, et al (5,580,896) discloses many heterocylic 4-oxo2-butenoic acid derivatives (column 13, lines 21-59; also
in columns 15+, examples 25,26,32,34,40,43-46, 77-79,
97,99,103,106,), which are useful for inhibiting colorectal
cancer (Abstract);
Giordani, et al (6,048,890) discloses 4-oxo-2-butenoic acid
derivatives said to be useful for treatment of AIDS
(column 1, line 8 and column 2, line 61; and,
Yonemeto, et al (6,083,985) recites a number of anti-tumor
or anti-AIDS agents that include heterocylic butenoic acid
derivatives.
For half a century, the most used anti-microbial agents
referenced above for prophylaxis and treatment of tuberculosis since 1952 is isoniazid (isonicotinic acid hydrazide
[INH]). One of the known complications of anti-tuberculosis
chemotherapy caused by this drug is liver dysfunction plus
a great number of other complications. The toxicity of INH
is also a serious problem frequently resulting in poisoning.
It is also known to be an acute/chronic hazards since INH is
an irritant of the skin, eyes, mucous membranes and upper
respiratory tract.
It appears from a review of the above that neither the
heterocyclic oxo-butenoic compounds or the benzoxazine
heterocyclic compounds of interest are disclosed nor is there
any report of activity against Mycobacterium tuberculosis.
Consequently, there is a need for an anti-tubercular drug
for humans or non-humans which mitigates the above men-

This application claims benefit of Ser. No. 60/292,985
filed May 23, 2001.
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FIELD OF THE INVENTION
This invention relates to novel methyl esters of substituted
4-oxo-2-butenoic acid and more particularly to certain moieties of these novel compounds and their close derivatives as
well as to the methods of their production and to the use of
these compounds as bacteriostatic agents (a chemical agent
that stops or inhibits the multiplication of bacteria) for
humans or non-humans against Mycobacterium
tuberculosis, and claims the benefit of priority of U.S.
Provisional Application Ser. No. 60/292,985 filed May 23,
2001.
BACKGROUND OF THE INVENTION
The infectious disease, tuberculosis (TB), is the leading
cause of death worldwide from a single human pathogen,
claiming more adult lives than diseases such as acquired
immunodeficiency syndrome (AIDS), malaria, diarrhea, leprosy and all other tropical diseases combined (Zumla A,
Grange J. B M J (1998) 316, 1962-1964). The organism
usually responsible is the tubercle bacillus, Mycobacterium
tuberculosis (MT), discovered by Robert Koch in 1882.
However, M. bovis, which infects cattle may also infect man
and M. africanum is a cause of TB in West Africa.
Furthermore, a number of normally non-pathogenic
mycobacteria, especially M. avium, M. intracellulare and M.
scrofulaceum, cause opportunistic infectious disease in
patients with AIDS (Horne N. 1996. Tuberculosis and other
mycobacteria diseases. In Mansons Tropical Diseases, 20'h
edn, Cook FEG (ed). WB Saunders: London; 971-1015).
Pulmonary TB, the most common type of the disease, is
usually acquired by inhalation of the bacillus from an
infectious patient and causes irreversible lung destruction.
About one third of the world's population is currently
infected with M. tuberculosis; 10% of those infected will
develop clinical diseases, particularly those who also have
the human immunodeficiency virus (HIV) infection (Zumla
A, Grange J. B M J (1998) 316, 1962-1964). With the
discovery of effective anti-mycobacteria agents (including
ethambutol, isoniazid, pyrazinamide, rifampicin and
streptomycin) and a reduction in poverty, there was a drastic
decline in the number of TB cases, especially in developed
nations. However, since the late 1980s, the number of cases
of TB throughout the world has been increasing rapidly
partly due to the emergence of multi-drug resistant M.
tuberculosis (C. E. Barry, III, Biochemical Pharmacology
(1997) 54, 1165-1172). According to the World Health
Organization (World Health Organization. 1993 92. per
Besra GS, Brennan P J. 1997. J Pharm Pharmacol 49 (Suppl.
1):25-30.s), it is expected that the annual death rate caused
by TB will reach an overwhelming 3.5 million people by the
year 2000. Thus the TB problem requires urgent attention.
Short course anti-TB regiments initially using at least three
first-line drugs (including isoniazid, rifampicin and
pyrazinamide) are often not effective due to an increase in
the number of tuberculosis strains that have become resistant
to current drugs. For example the World Health Organization
(WHO) recently reported that the death rate of patients with
multi-drug resistant (MDR) tuberculosis in the US was
approximately 70%. Current treatment is also very expen-
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tioned disadvantages of current bacteriostatic agents used as
drugs against TB bacterium in humans.

particular arrangement shown since the invention is capable
of other embodiments. Also, the terminology used herein is
for the purpose of description and not of limitation.

SUMMARY OF THE INVENTION
The first objective of the present invention is to provide a
bacteriostatic agent effective against Mycobacrium tuberculosis and other mycobacteria.
The second object of this invention is to provide a
bacteriostatic agent that is effective in humans or nonhumans against Mycobacterium tuberculosis and other
mycobacteria.

5

As earlier recited this application has been filed in order
to both disclose new methyl esters of substituted 4-0xo-2butenoic acids and to facilitate a fuller understanding of the
chemical scope of the methyl esters of substituted 4-oxo-2butenoic acids.

OF-12

A third object of this invention is to provide a bacteriostatic agent that is effective in humans or non-humans
against Mycobacterium tuberculosis and other mycobacteria
which is relatively inexpensive as a drug.
Another object of this invention is to provide novel
methyl esters of substituted 4-oxo-2-butenoic acids.
A preferred embodiment of the invention encompasses a
class of heterocyclics having the property of a bacteriostatic
agent against Mycobacterium tuberculosis and other mycobacterium comprising methyl esters of substituted 4-oxo-2butenoic acids and more specifically those derivatives: 4-(4E thoxyp hen y 1)-2-(N'-fluoren-9-ylidenehydrazino )-4oxo but-2-enoic acid methyl ester (OF-12); 4-(4Ethoxypheny 1)-2-(N'-fluoren-9-ylidenehydrazino )-2hydroxy-4-oxo-butyric acid methyl ester (OF-13); 2-(4Bromophenylamino)-5,5-dimethy 1-4-oxohex-2-enoic acid
methyl ester (OF-15); and the use of each in humans or
non-humans as therapeutic means for the eradication of
Mycobacterium tuberculosis and related mycobacteria from
the humans and nonhumans.

25

The methyl esters can be synthesized according to the
amination/dehydration steps designated as scheme I.
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More specifically this application is for anti-mycobacteria
compounds OF-12, OF-13, OF-15, which have been structurally shown in FIGS. 1-3, respectively. To facilitate a full
Further objects and advantages of this invention will be
understanding of the invention:
apparent from the following detailed description of presently
the compound designated as OF-12 is 4-( 4preferred embodiments which are illustrated structurally in
Ethoxypheny 1)-2-(N'-fl uoren-9-y lidenehydrazino )-4the accompanying drawings.
50
oxobut-2-enoic acid methyl ester;
the compound designated as OF-13 is 4-( 4BRIEF DESCRIPTION OF THE FIGURES
Ethoxypheny 1)-2-(N'-fl uoren-9-y lidenehydrazino )-2hydroxy-4-oxobutyric acid methyl ester;
FIG. 1 illustrates structurally a chemical compound desthe compound designated as OF-15 is 2-( 4ignated as OF-12.
55
Bromophenylamino)-5,5-dimethy 1-4-oxohex-2-enoic
acid methyl ester;
FIG. 2 illustrates structurally a chemical compound desThese compounds are highly active against Mycobacteignated as OF-13.
rium tuberculosis and have a very low toxicity, a lethal dose
FIG. 3 illustrates structurally a chemical compound des50 (LD 50 ) in animals. The percent activity and animal
ignated as OF-15.
60 toxicity for each compound is as follows: OF-12 (81 % and
LD 50 >1500 mg/kg), OF-13 (88% and LD 50 >1500 mg/kg),
and OF-15 (98% and LD 50 >1500 mg/kg),
DESCRIPTION OF THE PREFERRED
EMBODIMENTS
PREPARATION OF (OF-12)
Before explaining the disclosed embodiments of the
present invention in detail, it is to be understood that the
invention is not limited in its application to the details of the

45

65

EXAMPLE 1
The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fluoren-9ylidene-hydrazino )-4-oxobut-2-enoic acid methyl ester (OF-
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12). A solution of 5.0 g (0.02 moles) of methyl 4-pethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and 3.88 g
(0.02 moles) of hydrazone fluorenone (2) in 80 mL of
absolute toluene was refluxed for 3 hr 30 min with a
Dean-Stark trap (control for the end of the reaction was
carried by 1LC). The solution was cooled and the precipitate
was filtered and recrystallized from absolute benzenehexane (1:1) to give 3.4 g (68% yield) of yellow crystals, mp
135-137° c.

5

10

Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile; slightly soluble in ethanol, tetrachloromethane; insoluble in hexane and water.
15

PREPARATION OF (OF-13)
EXAMPLE 2

The preparation of 4-( 4-Ethoxyphenyl)-2-(N'-fluoren-9- 20
OF-12
ylidene-hydrazino )-2-hydroxy-4-oxobutyric acid methyl
ester (OF-13). A solution of 5.0 g (0.02 moles) of methyl
4-p-ethoxyphenyl-2-hydroxy-4-oxo-2-butenoate (1) and
3.88 g (0.02 moles) of fluorene-9-ylidene-hydrazine (2) in
It is seen from the Scheme 1 that OF-13 is an intermediate
80 mL of absolute benzene and absolute toluene (1:1) was 25 product during the synthesis of OF-12.
refluxed for 1 hr 30 min with a Dean-Stark trap (the end of
the reaction was determined by TLC), cooled and the
precipitate was filtered and recrystallized from benzenePREPARATION OF OF-15
diethyl ether-hexane mixture (1:3:2) to give 2.65 g (53%
30
yield) of colorless crystals with mp 114-116° C.
Solubility: highly soluble in DMSO, DMFA,
dichloroethane, acetonitrile, insoluble in hexane. The compound is not stable in solutions and decomposes quickly
when the solution is heated or stored for a long time with the
formation of OF-12.
The synthesis of (OF-12) and (OF-13) has been designated as Scheme I and is further illustrated by the preparation set forth below.

EXAMPLE 3
35

The preparation of 2-( 4-Bromophenylamino )-5,5dimethyl-4-oxohex-2-enoic acid methyl ester (OF-15).

40

+

45

50

A solution of 5.25 g (0.028 moles) of methyl 2-hydroxy-5,
5-dimethyl-4oxo-2-hexenoate (1) and 4.85 g (0.028 moles)
of p-bromoaniline (2) in 30 mL of absolute benzene was
refluxed for 2 hr with a Dean-Stark trap (Scheme 2). The
solution was cooled and the resulting precipitate of OF-15
was filtered and recrystallized from methanol to give 8.30 g
(87%) of yellow crystals with mp of 75-76° C.
The earlier referenced decarbonylation/transesterification
reactions designated as Scheme II is readily seen from the
following illustrated synthesis of OF-15.
CH\

TI

CH3-C-C-C=C-COOCH3

55

2

I

CH3

I
H

I
OH

OH

~COOCH3
C2HsO~
[__ _
0

NH

'N

cCo

OF-13

60

65
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-continued

and the percent inhibition in the presence of extract was
calculated by the following formulas:

CH\

IT

CH3-C-C-C=C-COOCH3

I

CH3

I

H

I

NH

¢

5

o/o/N = 100% - %GR
GR: Percent growth, G/: Growth index, IN: Percent inhibition

10

Br

OF-15

The bacteriostatic activity against Mycobacterium tuberculosis of the novel compounds (as earlier reported) was
realized by the following procedure. Compound processing:
Synthetic compounds OF-12, OF-13, OF-15, were each first
dissolved in 500 ul of dimethylsulfoxide (DMSO) in individual beakers and each placed on a rotary shaker overnight.
Distilled water was added to each to provide a final concentration of 10 mg/ml. Each solution was filter-sterilized
using Becton Dickinson 5 ml sterile syringes and Whatman
22 um sterile filters. Each of the filtered sterilized synthetic
test solutions (designated as synthons hereafter) were stored
at -20 degrees centigrade until used.
Culture media and bioassay analytical techniques:
BACTEC 12B Mycobacteria also known as Middlebrook
7H12 Medium was purchased from Becton Dickinson
(Pittsburgh, Pa.). It contains 7H9 broth base, casein
hydrolysate, bovine serum albumin, catalase and palmitic
acid labeled with 14C. It is specific for growing mycobacteria and is used in conjunction with the BACTEC brand 460
TB Analyzer. This Middlebrook 7H9 broth base media
consist of 4 ml of broth mixture included in a sealed bottle.
The culture used in the bioassay was M. tuberculosis (ATCC
25177). The synthons were added to Bactec 7H12 B+
bottled liquid media using Becton Dickinson 1 ml sterile
syringes to a final concentration of 0.1 mg/ml. To each of
these Bactec bottles, 100 ul of Bactec 7H12 B+ cultured M.
tuberculosis was inoculated using Becton Dickinson 1 ml
sterile syringes. Microbial growth activity in this culture
medium is indicated by the release of 14C0 2 into the
atmosphere of the sealed vial following the hydrolysis of
14
C-labeled palmitic acid by the microorganism. The
BACTEC 460 TB Analyzer: The gas in the atmosphere of
the sealed BACTEC 12B vial is aspirated from the vial via
a sterile needle attached to a robotic inside the BACTEC 460
TB Analyzer System. The BACTEC Analyzer operates by
initially drawing room air through a dust filter, a flush valve,
and an ion chamber transferring all 14 C02 into co2 trap
where it is retained. This process cleans the electrometer and
leaves it ready to start the next cycle. During the next cycle,
a pair of 18G needles are heated. A pump produces a partial
vacuum in the ion chamber used to lower the testing needles
through the rubber septum of the vial being tested. A vacuum
draws culture gas from the vial to the ion chamber. The
electrometer measures the very small current that the radioactive 14C0 2 produces in the ion chamber. Following
removal of the radioactive culture gas, fresh 5% C0 2 is
introduced into the medium headspace every time a vial is
tested, enhancing the growth of mycobacterium. The current
measured by the electrometer is amplified and displayed as
a growth index (GI). The growth index is measured on a
scale of 0 to 999 and is an indication of microbial growth
activity in the bottle. Usually, a GI of 10 or higher is an
indication of definite microbial growth. The percent growth,

%GR = G/(with no extract) x lOOo/o
G/(with the extract)
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Animal Toxicity Bioassay. Acute toxicity was studied on
white mice of both sexes with weight ranging between
18-26 grams under intraperitoneal injection of 2% solution
of tested compound in starch (the compound was dissolved
in starch slime and injected) on the basis of 0.1 ml of
solution per 10 g of the animal weight. Each dose was tested
on the group of 6 animals that were observed during 14 day
period. (This method was approved by the Pharmacology
committee of Russian Ministry of Health and has been
widely used since 1968.) Averaged lethal dose (LD 50 ) of the
compound was computed using results of experiments on
5-7 groups of animals using the method of Litchfield and
Wilkinson. (Belenkii M. L. "Elements of quantative determination of the pharmacological effect," Leningrad, 1963,
71 pages).
The disclosed invention makes it possible to produce and
isolate oxo-heterocyclics, which have the property of a
bacteriostatic agent toward Mycobacterium tuberculosis and
other mycobacteria.
ADVANTAGES OF THE DISCOVERY
This discovery has several advantages. In the background
there was a short description of one of the most used
first-line antimicrobial agents for prophylaxis and treatment
of tuberculosis since 1952. The name of this drug is isoniazid (isonicotinic acid hydrazide [INH]). Patients with a
recently positive protein positive derivative (PPD) skin test
and a normal chest x-ray routinely are given a 6-9 month
course of isoniazid. Liver dysfunction is one of known
complications of antituberculosis chemotherapy caused by
this drug among a great number of other complications when
isoniazid is co-administrated with other drugs (W. W. Yew,
Clinica Chimica Acta 313 (2001) 31-36).
The toxicity issue is also a serious problem. In the US: A
surveillance of cases of isoniazid poisoning by the American
Association of Poison Control Centers from 1985-1993
revealed a low number of 138 cases in 1985, with no
fatalities, and a high number of 2656 cases in 1991, with 6
fatalities. Mortality/Morbidity: Acute ingestion by adults
with as little as 1.5 g of isoniazid can lead to mild toxicity.
Ingestion of 6-10 g may be fatal, while ingestion of 15 g is
usually fatal if not appropriately treated. The overall mortality rate for acute isoniazid toxicity has been estimated to
be 19%. With current methods of supportive care, however,
this figure may be high. From 1972-1988, an estimated 152
fatalities were caused by isoniazid-related hepatitis. The
overall hepatitis-related death rates among patients using
isoniazid prophylaxis is approximately 0.001 %. Among
individuals who complete a full course of prophylaxis, the
hepatitis-related death rate has been calculated to be
23.2-57.9/100,000. The mortality rate among individuals
who develop overt isoniazid-induced hepatitis is 10%.
Isoniazid is also known to be an acute/chronic hazard.
This compound is an irritant of the skin, eyes, mucous
membranes and upper respiratory tract. It can cause harm by
ingestion, inhalation and skin absorption [Lenga, Robert E.
The Sigma-Aldrich Library of Chemical Safety Data. Edition 1. Sigma-Aldrich Corporation. Milwaukee, Wis. 1985.
p. 1114, #A].

US 6,683,110 Bl
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The acute tox1c1ty of isoniazid is as following: LCLo
(lowest published lethal concentration) for man is 100
mg/kg. In animal testing with white mouse LD 50 (lethal dose
50 percent kill) for isoniazid was shown to be 100 mg/kg
(the same intraperitoneal injection method (Krasil'nikov, I.
I.; Parfenov, A I.; Strel'nikov, Yu. E.; Smirnova, S. M.
Radiobiologiya (1973), 13(4), 551-4), which was used by us
to determine LD 50 dose). All toxicity information about
isoniazid can also be found on the web site: http://ntpserver.niehs.nih.gov/htdocs/Chem H&S/NTP Chem5/
Radian54-85-3.html
In addition there are a number of reports in recent
literature which suggest the importance of developing a new
treatment to combat strains of the deadly disease tuberculosis which have become resistant to current drugs.
By reference to page 6 first paragraph and in the following
it is seen that all of the specific compounds of the invention
exhibit at least 10 times lower acute toxicity compare to
isoniazid and high activity values. These compounds are
highly active against Mvcobacterium tuberculosis and have
a very low toxicity, a lethal dose 50 (LD 50 ) in animals. The
percent activity and animal toxicity for each compound is as
follows: OF-12 (81 % and LD 50 >1500 mg/kg), OF-13 (88%
and LD 50 >1500 mg/kg), and OF-15 (98% and LD 50 >1500
mg/kg),
The methyl esters of substituted 4-oxo-2-butenoic acid
compounds of the invention, which are unique in their
anti-tubercular activity, can be used in a pharmaceutical
composition comprising a non-toxic effective amount of the
referenced compound or a tautomeric form thereof or a
pharmaceutically acceptable salt thereof or pharmaceutically acceptable solvate thereof, and a pharmaceutically
acceptable carrier thereof.
For administration to man in the curative or prophylactic
treatment of tuberculosis, in vitro dosages of compounds of
the invention will generally be in the range of from 5 to 500
mg daily for an average adult patient (70 kg). Thus for a
typical adult patient, individual tablets or capsules contain
from 2-500 mg of active compound, in a suitable pharmaceutically acceptable vehicle or carrier, for administration in

single or multiple doses, once or several times per day.
Dosages for intraveneous, buccal or sublingual administration will typically be within the range of from 5-1000 mg
per single dose as required. In practice the physician will
determine the actual dosing regimen which will be most
suitable for an individual patient and it will vary with the
age, weight and response of the particular patient. The above
dosages are exemplary of the average case but there can be
individual instances in which higher or lower dosage ranges
may be merited, and such are within the scope of this
invention. The maximum non-toxic one time administration
dose for the compound(s) of the invention appears to be
1500 mg.
For human use, the compounds of the invention can be
administered alone or jointly, but will generally be administered in admixture with a pharmaceutical carrier selected
with regard to the intended route of administration and
standard pharmaceutical practice. For example, they may be
administered orally, buccally or sublingually, in the form of
tablets containing excipients such as starch or lactose, or in
capasules or ovules either alone or in admixture with
excipients, or in the form of elixirs or suspensions containing flavouring or colouring agents. The compounds may also
be injected parenterally, for example intraveneously,
intramuscularly, subcutaneously or intracoronarily. For
parenteral administration, they are best used in the form of
a sterile aqueous solution which may contain other
substances, for example enough salts or glucose to make the
solution isotonic with blood.
Thus in a further aspect the invention provides a method
for the treatment and/or prophylaxis of Mycobacterium
tuberculosis and related mycobacteria in a human or nonhuman which comprises administering an effective, nontoxic amount of a specific compounds according to the
invention or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof and/or a pharmaceutically
acceptable solvate thereof, to a tubercular human or nonhuman mammal in need thereof.
Tables 1, 2 and 3 disclose additional methyl esters of
4-oxo-butenoic acids

5

10

15

20

25

30

35

TABLE 1
Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid.

wherein R 1 and R 2 are organic substituent groups.
# Structure

Name
2-(N'-Fluoren-9-ylidene-hydrazino )-4-oxo-4p-tolyl-but-2-enoic acid methyl ester

0

HN....._
N

~

US 6,683,110 Bl
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TABLE 1-continued

Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid.

wherein R1 and R2 are organic substituent groups.

# Structure

Name

4-( 4-Ethyl-phenyl)-2-(N'-fluoren-9-ylidenehydrazino )-4-oxo-but-2-enoic acid methyl ester

0

HN....._
N

~
2-(N' -Fluoren-9-ylidene-hydrazino)-4-oxo-4o-to ly l-but-2-enoic acid methyl ester

3

0

HN....._
N

~
2-(N' -Fluoren-9-ylidene-hydrazino)-4-oxo-4m-tol y l-but-2-enoic acid methyl ester

4

0

HN....._
N

~
5

4-( 4-Butyl-phenyl)-2-(N' -fluoren-9-ylidenehydrazino )-4-oxo-but-2-enoic acid methyl ester

0

HN....._
N

~

US 6,683,110 Bl
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TABLE 1-continued

Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid.

wherein R1 and R2 are organic substituent groups.
# Structure

Name
4-( 4-tert-Butyl-phenyl)-2-(N'-fluoren-9-ylidenehydrazino )-4-oxo-but-2-enoic acid methyl ester

0

HN....._
N

~
4-(2,4-Dimethyl-phenyl)-2-(N'-fluoren-9-ylidenehydrazino )-4-oxo-but-2-enoic acid methyl ester

0

HN....._
N

~
4-(3,4-Dimethyl-phenyl)-2-(N'-fluoren-9-ylidenehydrazino )-4-oxo-but-2-enoic acid methyl ester

0

HN....._
N

~
4-(2,5-Dimethyl-phenyl)-2-(N'-fluoren-9-ylidenehydrazino )-4-oxo-but-2-enoic acid methyl ester

9

0

HN....._
N

~

US 6,683,110 Bl
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TABLE 1-continued

Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid.

wherein R1 and R2 are organic substituent groups.
# Structure

Name

2-(N' -Fluoren-9-ylidene-hydrazino)-4-oxo-4(2, 4, 6-trimeth yl-p hen yl)-but-2-enoic acid methyl ester

0
/CH3
0
CH3

0

HN'-.

N

cQ)
#

2-(N'-Fluoren-9-ylidene-hydrazino)-4-( 4-methoxyphenyl)-4-oxo-but-2-enoic acid methyl ester

0
/CH3
0
0

HN'-

N

~
#

4-(2,4-Dimethoxy-phenyl)-2-(N'-fluoren-9-ylidenehydrazino )-4-oxo-but-2-enoic acid methyl ester

0
/CH3
0
0

HN'-

N

~
#

13

4-(3,5-Dimethoxy-phenyl)-2-(N'-fluoren-9-ylidenehydrazino )-4-oxo-but-2-enoic acid methyl ester

OCH3

0

HN'N

~

US 6,683,110 Bl
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TABLE 1-continued

Table of Some Derivatives of the Methyl Esters of 4-oxo-butenoic acid.

R'do/°"
0

0

R1

wherein R 1 and R2 are organic substituent groups.

# Structure

Name

14

4-(2,5-Dimethoxy-phenyl)-2-(N'-fluoren-9-ylidenehydrazino )-4-oxo-but-2-enoic acid methyl ester

0

HN....._
N

~
wherein R 1 and R2 are organic substituent groups.

H;Cw
'™)()
n,cw
'™VB'
n,cw
'™)()
n,cw

TABLE II

# Structure

~

H3C

Name

2-(2-Bromo-phenylamino)-5,5-dimethyl-4oxo-hex-2-enoic acid methyl ester

,.....-CH3

0

0

Br

2

I#

~

H3C

2-(3-Bromo-phenylamino)-5,5-dimethyl-4oxo-hex-2-enoic acid methyl ester

,.....-CH3

0

0

3

~

H3C

2-(2-Chloro-phenylamino)-5,5-dimethyl-4oxo-hex-2-enoic acid methyl ester

,.....-CH3

0

0

I#

Cl

4

~

H3C

,.....-CH3

0

0

'™VO

2-(3-Chloro-phenylamino)-5,5-dimethyl-4oxo-hex-2-enoic acid methyl ester

US 6,683,110 Bl
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TABLE II-continued

# Structure

Name

2-(4-Chloro-phenylamino)-5,5-dimethyl-4oxo-hex-2-enoic acid methyl ester

2-(3-Fluoro-phenylamino )-5 ,5-dimethyl-4-oxohex-2-enoic acid methyl ester

2-(4-Fluoro-phenylamino )-5 ,5-dimethyl-4-oxohex-2-enoic acid methyl ester

2-(4-Bromo-2-methyl-phenylamino )-5 ,5dimethyl-4-oxo-hex-2-enoic acid methyl ester

2-(4-Bromo-3-methyl-phenylamino )-5 ,5dimethyl-4-oxo-hex-2-enoic acid methyl ester

2-(4-Chloro-2-methyl-phenylamino )-5 ,5dimethyl-4-oxo-hex-2-enoic acid methyl ester

US 6,683,110 Bl
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TABLE II-continued

# Structure

Name

2-(2,4-Dichloro-phenylamino )-5 ,5-dimethyl-4oxo-hex-2-enoic acid methyl ester

4-(1-Methoxycarbonyl-4,4-dimethyl-3-oxopent-1-enylamino)-benzoic acid ethyl ester

TABLE 3
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids.

#

Structure

Name

4-(1-Methoxycarbonyl-3-oxo-3-phenylpropenylamino)-benzoic acid ethyl ester

2

2-(1-Methoxycarbonyl-3-oxo-3-phenylpropenylamino)-benzoic acid ethyl ester

3

2-(3,4-Dichloro-phenylamino)-4-oxo-4phenyl-but-2-enoic acid methyl ester

US 6,683,110 Bl
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TABLE 3-continued

Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids.
#

Structure

Name

2-(1,5-Dimethyl-3-oxo-2-phenyl-2,3dihydro-lH-pyrazol-4-ylamino)-4-oxo-4phenyl-but-2-enoic acid methyl ester

4
0

/CH3
0
0

HN

CH3

o):j'rn,
I

C6Hs

5

2-{N' -[ 1-( 4-Chloro-phenyl)-ethylidene]hydrazino }-4-oxo-4-phenyl-but-2-enoic
acid methyl ester

0

/CH3
0
0

HN'-

N

n,c~
#

Cl
2-{N' -[ (4-Methoxy-phenyl)-phenylmethylene ]-hydrazino }-4-oxo-4-phenylbut-2-enoic acid methyl ester

0

/CH3
0
0

2-(N'-Benzhydrylidene-hydrazino )-4-oxo4-phenyl-but-2-enoic acid methyl ester

7

0

HN'N

du
2-{N' -[ (2-Bromo-phenyl)-phenylmethylene ]-hydrazino }-4-oxo-4-phenylbut-2-enoic acid methyl ester

8

0

HN'-.

N

Br

dD

US 6,683,110 Bl
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TABLE 3-continued

Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids.
#

Structure

Name

2-(N'-Benzhydrylidene-hydrazino )-4-( 4ethoxy-phenyl)-4-oxo-but-2-enoic acid
methyl ester

HN-.....

0

N

du
4-( 4-Ethoxy-phenyl)-4-oxo-2-[N'-(phenylo-tolyl-methylene)-hydrazino ]-but-2-enoic
acid methyl ester

HN-.....

0

dD
11

2-(2-Cyano-phenylamino )-4-(4-fluorophenyl)-4-oxo-but-2-enoic acid methyl ester

F

0

HNX)
I#
NC

12 F
0

0

2-(N'-Benzhydrylidene-hydrazino )-4-( 4fluoro-phenyl)-4-oxo-but-2-enoic acid
methyl ester

HN-.....

du
13

F

2-(N'-Di-p-tolylmethylene-hydrazino )-4-( 4fluoro-phenyl)-4-oxo-but-2-enoic acid
methyl ester

US 6,683,110 Bl
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TABLE 3-continued
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids.
#

Structure

Name

2-(N'-Fluoren-9-ylidene-hydrazino)-4-(4methoxy-phenyl)-4-oxo-but-2-enoic acid
methyl ester

0

HN......_
N

~
2-( 4-Bromo-phenylamino )-4-( 4-ethoxyphenyl)-4-oxo-but-2-enoic acid methyl ester

0

0

HN~

~

Br

16

Cl

4-( 4-Chloro-phenyl)-4-oxo-2-(2,4,6trimethyl-phenylamino)-but-2-enoic acid
methyl ester

17

Cl

2-[3-( 4-Chloro-phenyl)-1methoxycarbonyl-3-oxo-propenylamino ]benzoic acid ethyl ester

18

Cl

4-( 4-Chloro-phenyl)-2-{N'-[ 1-( 4-ethoxyphenyl)-ethylidene ]-hydrazino }-4-oxo-but2-enoic acid methyl ester

US 6,683,110 Bl
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TABLE 3-continued

Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids.
#

Structure

Name

19

Cl

2-(N'-Benzhydrylidene-hydrazino )-4-( 4chloro-phenyl)-4-oxo-but-2-enoic acid
methyl ester

0

HN......_
N

du
20

2-{N' -[ (2-Bromo-phenyl)-phenylmethylene ]-hydrazino }-4-( 4-chlorophenyl)-4-oxo-but-2-enoic acid methyl ester

Cl

0

HN......_
N

Br

dD
21

Br

4-( 4-Bromo-phenyl)-2-(3,4-dimethylphenylamino )-4-oxo-but-2-enoic acid
methyl ester

22

Br

2-(N'-Benzhydrylidene-hydrazino )-4-( 4bromo-phenyl)-4-oxo-but-2-enoic acid
methyl ester

0

HN......_
N

du
23

4-( 4-Bromo-phenyl)-4-oxo-2-[N'-(phenylo-tolyl-methylene)-hydrazino ]-but-2-enoic
acid methyl ester

Br

0

HN

o\5

US 6,683,110 Bl
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TABLE 3-continued
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids.
#

24

Structure

Name

Br

4-( 4-Bromo-phenyl)-2-(N' -di-ptolylmethylene-hydrazino )-4-oxo-but-2enoic acid methyl ester

2-( 4-Bromo-phenylamino )-4-oxo-4-p-tolylbut-2-enoic acid methyl ester

HN~

0

~

Br
2-(3,4-Dimethyl-phenylamino )-4-oxo-4-ptolyl-but-2-enoic acid methyl ester

5,5-Dimethyl-4-oxo-2-phenylamino-hex-2enoic acid methyl ester

5,5-Dimethyl-4-oxo-2-p-tolylamino-hex-2enoic acid methyl ester

29

~

H3CJ:3
H3C'

~
0

1

~

/CH3

'o

HN......_
N

\)

2-(N'-Benzylidene-hydrazino)-5,5dimethyl-4-oxo-hex-2-enoic acid methyl ester

US 6,683,110 Bl
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TABLE 3-continued
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids.
#

Structure

30

H3C..J:3
H3C'

Name

~

"'lf'"

1

~

2-[N'-( 4-Bromo-benzylidene)-hydrazino ]5 ,5-dimethyl-4-oxo-hex-2-enoic acid
methyl ester

/CH3

'o

HN....._

0

N

31

~

H3C..J:3
H3C'

"'lf'"

»"
1
/CH3

~

2-(N'-Benzhydrylidene-hydrazino )-5 ,5dimethyl-4-oxo-hex-2-enoic acid methyl ester

'o

HN....._

0

N

dD
32

~

H3C..J:3
H3C'

"'lf'"
0

1

~

5,5-Dimethyl-4-oxo-2-[N'-(phenyl-o-tolylmethylene)-hydrazino ]-hex-2-enoic acid
methyl ester

/CH3

'o

HN....._

dD
4-0xo-6-phenyl-2-p-tolylamino-hexa-2,5dienoic acid methyl ester

33

34

2-(N'-Benzhydrylidene-hydrazino )-6-( 4fluoro-phenyl)-4-oxo-hexa-2,5-dienoic acid
methyl ester

F

0

HN....._
N

du

US 6,683,110 Bl
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TABLE 3-continued

Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids.

#

Structure

Name

2-( 4-Bromo-phenylamino )-4-furan-2-yl-4oxo-but-2-enoic acid methyl ester

2-(3,4-Dimethyl-phenylamino )-4-furan-2yl-4-oxo-but-2-enoic acid methyl ester

2-(N'-Benzhydrylidene-hydrazino )-4-furan2-yl-4-oxo-but-2-enoic acid methyl ester

4-Furan-2-yl-4-oxo-2-[N'-(phenyl-o-tolylmethylene)-hydrazino ]-but-2-enoic acid
methyl ester

2-(N'-Fluoren-9-ylidene-hydrazino)-4furan-2-yl-4-oxo-but-2-enoic acid methyl ester

US 6,683,110 Bl
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TABLE 3-continued
Table of Derivatives of Methyl Esters of 4-oxo-butenoic acids.
#

Structure

Name

2-(N'-Fluoren-9-ylidene-hydrazino)-4-(4nitro-phenyl)-4-oxo-but-2-enoic acid
methyl ester

0

HN....._
N

~
0

2-(N'-Benzhydrylidene-hydrazino )-4-( 4nitro-phenyl)-4-oxo-but-2-enoic acid
methyl ester

HN....._

du
While the invention has been described, disclosed, illustrated and shown in various terms of certain embodiments or
modifications which it has presumed in practice, the scope
of the invention is not intended to be, nor should it be
deemed to be, limited thereby and such other modifications
or embodiments as may be suggested by the teachings herein
are particularly reserved especially as they fall within the
breadth and scope of the claims here appended.
We claim:
1. A compound of a 4-oxo-2-butenoic acid methyl ester
derivative, having the property of bacteriostatic activity
against Mycobacteria, the compound consisting of:
4-( 4-Ethoxyphenyl)-2-(N'-fiuoren-9-y lidenehydrazino )2-hydroxy-4-oxobutyric acid methyl ester.
2. A compound of a 4-oxo-2-butenoic acid methyl ester
derivative having the property of bacteriostatic activity
against Mycobacteria, the compound consisting of:
2-( 4-Bromophenylamino )-5 ,5-dimethyl-4-oxohex-2enoic acid methyl ester.
3. A method for the treatment and/or prophylaxis of
mycobacteria in a human or a non-human which comprises
administering to said human or non-human in need thereof,
an effective, non-toxic amount of a compound consisting of
a 4-oxo-2-butenoic acid methyl ester derivative or a tauto-
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meric form thereof and/or a pharmaceutically acceptable salt
thereof and/or a pharmaceutically acceptable solvate thereof
which compound is 4-(4-Ethoxyphenyl)-2-(N'-fiuoren-9ylidenehydrazino )-4-oxobut-2-enoic acid methyl ester.
4. A method for the treatment and/or prophylaxis of
mycobacteria in a human or a non-human which comprises
administering to said human or non-human in need thereof,
an effective, non-toxic, amount of a compound consisting of
a 4-oxo-2-butenoic acid methyl ester derivative or a tautomeric form thereof and/or a pharmaceutically acceptable salt
thereof and/or a pharmaceutically acceptable solvate thereof
which compound is 4-(4-Ethoxyphenyl)-2-(N'-fiuoren-9ylidenehydrazino )2-hydroxy-4-oxobutyric acid methyl
ester.
5. A method for the treatment and/or prophylaxis of
mycobacteria in a human or non-human which comprises
administering to said human or non-human in need thereof,
an effective, non-toxic amount of a compound consisting of
a 4-oxo-2-butenoic acid methyl ester derivative or a tautomeric form thereof and/or a pharmaceutically acceptable salt
thereof and/or a pharmaceutically acceptable solvate thereof
which compound is 2-( 4-Bromopheny lamina )-5 ,5dimethyl-4-oxohex-2-enoic acid methyl ester.

* * * * *

